Phase 1 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with cancer (confirmed by a tissue or cell sample) that has spread or cannot be surgically removed, and your doctor thinks this radiation treatment is appropriate for you.
- You are over 18 years old.
- You are well enough to carry out some daily activities (your doctor will assess this using a standard scale).
- You have severe pain that spreads from your lower back to your upper abdomen in a belt-like pattern, and your pain is rated at least 5 out of 10 even while taking pain medication.
- Your scans (CT, PET/CT, or MRI) show that the cancer is affecting a specific nerve cluster in the abdomen called the celiac plexus — this includes all pancreatic cancers, or other cancers that show signs of involving nearby blood vessels or surrounding tissue (confirm with trial site).
- You have had a recent abdominal scan (CT, PET/CT, or MRI) taken within the last 28 days that clearly shows the treatment area.
- If you are currently receiving chemotherapy or other cancer treatments, these must be paused at least 1 week before and after the radiation treatment.
- You are able to understand the study information and are willing to sign a consent form.
Who may not be able to join:
- You have previously had radiation treatment to your upper abdomen, especially in the same area being considered for this treatment.
- You are currently pregnant or breastfeeding.
- You have certain conditions that increase the risk of side effects from radiation, such as inflammatory bowel disease or scleroderma.
- Women who could become pregnant must have a negative pregnancy test within 14 days of joining the study (unless your doctor determines this is not needed, in which case that decision must be documented).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lauren Henke, MD, MSCI, Case Comprehensive Cancer Center, University Hospitals
Phone: (218) 234 -6429
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Feasibility of the simulation-free adaptive radiotherapy workflow, as measured by rate of successful completion of treatment; Feasibility of the simulation-free adaptive radiotherapy workflow, as measured by rate of compliance with priority level 1 dose constraints
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.